Citadel Advisors’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Citadel Advisors’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,600	Closed	-$271K	–	14228
2022 Q2	$271K	Buy	+3,600	New	+$160K	﹤0.01%	10041
2021 Q4	–	Sell	-7,500	Closed	-$498K	–	15314
2021 Q3	$498K	Buy	7,500 +3,100	+70%	+$221K	﹤0.01%	9880
2021 Q2	$343K	Buy	+4,400	New	+$325K	﹤0.01%	10947
2021 Q1	–	Sell	-4,300	Closed	-$524K	–	13938
2020 Q4	$524K	Buy	4,300 +1,500	+54%	+$164K	﹤0.01%	8064
2020 Q3	$245K	Buy	+2,800	New	+$195K	﹤0.01%	8481

Citadel Advisors's TPTX Position: Q3 2022 in Review

Citadel Advisors sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 165,650 shares — an estimated $12.5M sold.

Citadel Advisors first reported a position in TPTX in Q2 2019 and held it in 11 quarters. The position peaked at $30.8M in Q4 2021. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Citadel Advisors reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Citadel Advisors sold 165,650 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $12.5M.
Citadel Advisors first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 11 quarters.
Citadel Advisors's Turning Point Therapeutics, Inc. Common Stock position peaked at $30.8M in Q4 2021.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.